Equities research analysts at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN - Get Free Report) in a note issued to investors on Tuesday, Marketbeat reports. The brokerage set an "in-line" rating and a $155.00 price target on the biotechnology company's stock. Evercore ISI's price objective would suggest a potential upside of 10.70% from the stock's previous close.
Several other equities analysts also recently commented on RGEN. Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research report on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of "Hold" and a consensus target price of $178.64.
Check Out Our Latest Analysis on Repligen
Repligen Trading Up 0.5 %
Repligen stock traded up $0.68 during trading on Tuesday, hitting $140.02. The company had a trading volume of 623,142 shares, compared to its average volume of 650,573. The company's 50 day simple moving average is $156.18 and its 200-day simple moving average is $148.32. The stock has a market cap of $7.86 billion, a price-to-earnings ratio of -274.55, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 1-year low of $113.50 and a 1-year high of $200.03.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, analysts expect that Repligen will post 1.72 EPS for the current fiscal year.
Insider Buying and Selling at Repligen
In related news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Repligen
Hedge funds have recently made changes to their positions in the business. Signaturefd LLC boosted its stake in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. purchased a new position in Repligen during the fourth quarter worth about $29,000. Raiffeisen Bank International AG purchased a new position in Repligen during the fourth quarter worth about $29,000. Resources Management Corp CT ADV purchased a new position in Repligen during the third quarter worth about $37,000. Finally, Quarry LP raised its holdings in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 239 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Repligen Company Profile
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
